Oviduct contractility in non-pregnant rats: changes in estrous cycle and effects of estrogen and progesterone antagonists

This study aimed to systematically characterize oviduct contractility across the estrous cycle and to examine the regulatory roles of estradiol and progesterone using receptor antagonists and molecular docking to explore both receptor-mediated and ion channel pathways. Female Wistar rats (n = 48) were used for this purpose. Oviducts were collected during proestrus, estrus, metestrus, and diestrus, and spontaneous contractions were recorded using an isometric force transducer. Serum levels of estradiol, progesterone, luteinizing hormone, follicle-stimulating hormone, and prolactin were measured through enzyme-linked immunosorbent assay (ELISA). To understand hormonal regulation, tamoxifen (10 mg/kg) was administered during proestrus, and mifepristone (5 mg/kg) was administered during metestrus. Immunofluorescence (IF) study was performed to evaluate expression of the estrogen, progesterone, and glucocorticoid receptors (ER, PR, and GR). Molecular docking analysis assessed interactions of the antagonists with estrogen and progesterone receptors and ion channels. Oviduct contractility was observed noticeably highest during proestrus (high estradiol) and lowest in metestrus and diestrus phases (high progesterone). Tamoxifen significantly reduced contraction parameters (P < 0.001) and estradiol levels, while mifepristone notably increased contraction force (P < 0.01), elevated estradiol levels (P < 0.001), and decreased the proportion of progesterone hormone. The IF study indicated suppression of ER, PR, and GR expression following treatment with mifepristone. Docking analysis revealed that tamoxifen interacted with potassium channels and ERβ, while mifepristone showed high affinity for PR, GR, and calcium channels. These findings highlight that oviduct contractility is dynamically regulated across the estrous cycle through both receptor-mediated and potential non-receptor and non-genomic pathways involving ion channels.

Authors

Institutions

Publication Details

Journal
Reproduction
Published
2025-09-02
DOI
https://doi.org/10.1530/rep-25-0096
Primary Topic
Ovarian function and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oviduct contractility in non-pregnant rats: changes in estrous cycle and effects of estrogen and progesterone antagonists

Richa Singh, Shristi Modanwal, Sanjeev Kumar Mahto, Parul Sharma et al.
Reproduction
Ovarian function and disorders
article

Oviduct contractility in non-pregnant rats: changes in estrous cycle and effects of estrogen and progesterone antagonists

Richa Singh, Shristi Modanwal, Sanjeev Kumar Mahto, Parul Sharma, Amaresh Kumar Singh, Himanshu Ranjan, Sangita Agarwal
article en

Abstract

This study aimed to systematically characterize oviduct contractility across the estrous cycle and to examine the regulatory roles of estradiol and progesterone using receptor antagonists and molecular docking to explore both receptor-mediated and ion channel pathways. Female Wistar rats (n = 48) were used for this purpose. Oviducts were collected during proestrus, estrus, metestrus, and diestrus, and spontaneous contractions were recorded using an isometric force transducer. Serum levels of estradiol, progesterone, luteinizing hormone, follicle-stimulating hormone, and prolactin were measured through enzyme-linked immunosorbent assay (ELISA). To understand hormonal regulation, tamoxifen (10 mg/kg) was administered during proestrus, and mifepristone (5 mg/kg) was administered during metestrus. Immunofluorescence (IF) study was performed to evaluate expression of the estrogen, progesterone, and glucocorticoid receptors (ER, PR, and GR). Molecular docking analysis assessed interactions of the antagonists with estrogen and progesterone receptors and ion channels. Oviduct contractility was observed noticeably highest during proestrus (high estradiol) and lowest in metestrus and diestrus phases (high progesterone). Tamoxifen significantly reduced contraction parameters (P < 0.001) and estradiol levels, while mifepristone notably increased contraction force (P < 0.01), elevated estradiol levels (P < 0.001), and decreased the proportion of progesterone hormone. The IF study indicated suppression of ER, PR, and GR expression following treatment with mifepristone. Docking analysis revealed that tamoxifen interacted with potassium channels and ERβ, while mifepristone showed high affinity for PR, GR, and calcium channels. These findings highlight that oviduct contractility is dynamically regulated across the estrous cycle through both receptor-mediated and potential non-receptor and non-genomic pathways involving ion channels.

ReproductionVol. 170(4)
Indian Institute of Information Technology Allahabad (IN), Institute of Medical Sciences (IN), Banaras Hindu University (IN)
Openalex Percentile: Top 69%
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.